Trial Profile
A phase I/IIa study of zona pellucida antigens (ZP) in female patients with metastasised ovarian cancer
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 31 Oct 2014
Price :
$35
*
At a glance
- Drugs Zona pellucida vaccine (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 31 Oct 2014 New trial record
- 27 Oct 2014 Pantarhei Bioscience in collaboration with HRA Pharma plans to initiate this trial by 2016.